Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
PRIORITY PRESS - 52nd Annual Meeting and Exposition of the American Society of Hematology
Validating the Subcutaneous Route in Multiple Myeloma Maintenance Therapy
Orlando, Florida / December 4-7, 2010
Orlando - New phase III data demonstrating that subcutaneous (s.c.) administration of a drug commonly administered intravenously (i.v.) is as effective but better tolerated in the treatment of multiple myeloma (MM) has been proposed as a...
PRIORITY PRESS - 52nd Annual Meeting and Exposition of the American Society of Hematology
Defining Disease Burden and Treatment Efficacy in Paroxysmal Nocturnal Hemoglobinuria
Orlando, Florida / December 4-7, 2010
Orlando - Paroxysmal nocturnal hemoglobinuria (PNH) confers a high risk of morbidity and mortality. In half of patients, the severe and persistent hemolysis that characterizes the disease leads to thromboses involving the liver and cerebral...
PRIORITY PRESS - Canadian Cardiovascular Congress 2010
CCS Antiplatelet Therapy Guidelines: Implementation of an Evidence-based Systematic Approach
Montreal, Quebec / October 23-27, 2010
TO EARN CME CREDITS, PLEASE SEE BELOW Montreal - The Canadian Cardiovascular Society Antiplatelet Therapy Guidelines 2010 include an expanded list of antiplatelet strategies, including a more potent regimen, to reflect data published...
RESOURCE LINE
VACCINE
October-December 2010
Broadening HPV vaccination to boys, men Elbasha E, Dasbach E. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010;28:6858-67. Kim J. Targeted human papillomavirus vaccination of men who have sex with men in...
PHYSICIAN PERSPECTIVE - Viewpoint Based on the following articles: BJU Int 15 Oct 2010;Epub ahead of print, J Sex Med 2010;7(11):3725-35.
Canadian Data on Mild Erectile Dysfunction: Often an Early Sign of Vascular Disease
November 2010
INTRODUCTION Erectile dysfunction (ED) is both a common source of diminished quality of life (QoL) and a signal for potential serious underlying pathologies. Of these, impairment in blood flow secondary to progressive vascular disease is...
MEDICAL FRONTIERS - 61st Annual Refresher Course for Family Physicians
Disease Prevention in Primary Care
McGill University, Montreal, Quebec / November 28-December 1, 2010
Which Lifestyle Changes Are Effective? Lifestyle measures can promote overall health, prevent disease and extend life. In patients already taking antihypertensive or lipid-lowering therapy, lifestyle modification may be more effective than...
PRIORITY PRESS - 61st Annual Refresher Course for Family Physicians
Addressing Cardiovascular Health and Back Pain
McGill University, Montreal, Quebec / November 28-December 1, 2010
Which Lifestyle Changes Are Effective? Lifestyle measures can promote overall health, help effect disease prevention and modestly extend life and may be more effective than increasing doses of antihypertensive and/or lipid-lowering...
PRIORITY PRESS - A Canadian Debate on Antiplatelet Therapy - Post 83rd Scientific Sessions of the American Heart Association
The Great Debate In Antiplatelet Therapy: The Trials, The Data, The Patients
Hamilton, Ontario / November 17, 2010
TO EARN CME CREDITS, PLEASE SEE BELOW Hamilton - Choosing the appropriate antiplatelet for patients with acute coronary syndromes and those undergoing percutaneous coronary interventions is becoming more complicated as the antiplatelet...
PRIORITY PRESS - 43rd Annual Meeting and Scientific Exhibition of the American Society of Nephrology (ASN)
Reducing Cardiovascular Risk in Chronic Kidney Disease
Denver, Colorado / November 16-21, 2010
Denver - For the first time, lipid-lowering therapy has demonstrated the potential to reduce cardiovascular (CV) risk in patients with chronic kidney disease. Treatment with a fixed-dose combination therapy, ezetimibe 10 mg/simvastatin 20...